DESCRIPTION

AGS has developed preliminary advice to help clinicians in assisting their patients and surrogates to be fully informed about the risks and benefits of aducanumab based on the available data.

Writing Workgroup

Soo Borson, MD

Peter Hollman, MD, AGSF

Nancy Lundebjerg, MPA

Todd Semla, PharmD, MS, AGSF

Mark Supiano, MD, AGSF

Reviewers

William Lyons, MD, AGSF

Belinda Setters, MD, AGSF

Eric Widera, MD

Final approval

The AGS Executive Committee reviewed and approved this document and made recommendations on behalf of the AGS Board of Directors on July 15, 2021.